Uterine fibroid

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Retrieved on: 
Tuesday, July 5, 2022
Department, Financial compensation, FDA, CF, Mutation, Science, University of Chicago, Patient, Savannah State University Office of Graduate Studies and Sponsored Research, Kidney, CEO, Massachusetts Institute of Technology, United States Attorney General, GLOBE, Â, European Commission, CFA, Degenerative disease, Cancer, Initial public offering, RMAS, Eukaryotic ribosome, MBA, Department of Human Services and Health, Fast Track, Orphan, Humanitarian use licenses, Food, Autosome, BS, Royal commission, Roivant Sciences, RNA, Psoriasis, Polycystic kidney disease, University, Cystic fibrosis, Acquisition, JD, Regulation of tobacco by the U.S. Food and Drug Administration, Overactive bladder, NASDAQ, Uterine fibroid, Management, Pharmaceutical industry

WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board. Following these changes, Eloxx’s board is now comprised of five directors.

Key Points: 
  • Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board.
  • Following these changes, Eloxxs board is now comprised of five directors.
  • I am passionate about companies like Eloxx that are focused on addressing unmet needs for underserved patient populations.
  • I am excited to join the board of Eloxx and to contribute to the companys work in developing therapies for rare diseases, said Ms. Androski.

New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options

Retrieved on: 
Friday, July 1, 2022
Education, Influencer, Health, Women, Communications, Health Technology, Medical Devices, Digital Marketing, Surgery, Consumer, Other Education, HOLX, Patient, Life, Science, Research, Clothing, Breast cancer, The Harris Poll, Health, Uterine fibroid, COVID-19, Sale, Company, Fibroid, Female, Pain, Awareness, United States Department of Health and Human Services, Woman, Cyst, Uterus, Hysterectomy, Nasdaq, Human services, Cervical cancer, Polyp, Infertility, Solution, Language, Leadership, Physician, News, Mammography, Pharmaceutical industry, Birth control, Health insurance, Online gambling, Hologic

A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.

Key Points: 
  • A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.
  • Today, in conjunction with the start of Fibroid Awareness Month, Hologic is proud to announce the launch of Hey, U!, an educational campaign focused on uterine health.
  • "There is a sizeable knowledge gap when it comes to overall uterine health, including symptoms and treatment options for common issues like uterine fibroids."
  • Additional content includes a patient symptom quiz, downloadable discussion guides and information on various fibroid treatment solutions.

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Retrieved on: 
Tuesday, June 28, 2022
SIX Swiss Exchange, Patient, Gynaecology, Marketing, Company, Hormone, Birth, MHRA, Royal commission, Birth certificate, Quality of life, Urology, Osteoporosis, Drug development, Nasdaq, Pregnancy, Coronavirus, Uterine fibroid, NDA, Security (finance), FDA, European, ABT, Woman, Anemia, Nephrology Dialysis Transplantation, Uterus, SEC, Risk, Central Research Laboratories, Solution, CEO, Report, New Drug Application, Linzagolix, European Commission, Menopause, Investor, Private Securities Litigation Reform Act, Health, U.S. Securities and Exchange Commission, NASDAQ, Mental health, Bloating, Review, Anxiety, Fertility, Adult, Pain, Theramex, Endometriosis, Gonadotropin-releasing hormone, PDUFA, Medicines and Healthcare products Regulatory Agency, Medical device, Pharmaceutical industry, Birth control, EU, Kissei, UF

Yselty is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.

Key Points: 
  • Yselty is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
  • The MHRA approval follows the granting of marketing authorization by the European Commission earlier in June 2022.
  • For women with UF who cannot or do not want to take hormones, Yselty is the first and only approved oral GnRH antagonist with a non-hormonal dosing option.
  • As the first and only approved GnRH antagonist to offer flexible dosing options with and without additional hormonal therapy, we hope to redefine care for women suffering from uterine fibroids.

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

Retrieved on: 
Friday, June 17, 2022
Medical Supplies, Health, Consumer, Women, Pharmaceutical, Biotechnology, Solution, Gonadotropin-releasing hormone, Fertility, Uterine fibroid, Nasdaq, CHMP, Menopause, Contraindication, Endometriosis, Urology, Theramex, Central Research Laboratories, Pregnancy, Linzagolix, SIX Swiss Exchange, Kissei, Birth, Committee, Physician, Health, Nephrology Dialysis Transplantation, European Commission, European Directive on Traditional Herbal Medicinal Products, Partnership, Adult, Patient, Life, Committee for Medicinal Products for Human Use, Osteoporosis, ABT, Woman, EC, Pharmaceutical industry, UF, EU

The European Commission (EC) has granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Key Points: 
  • The European Commission (EC) has granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.
  • The EC decision follows the Committee for Medicinal Products for Human Use (CHMP) confirmation of positive opinion in April 2022.
  • Linzagolix is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
  • Uterine Fibroids affect 25% of women within reproductive age, many with severe symptoms requiring surgery.

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
Thursday, June 16, 2022
Review, Uterine fibroid, FDA, USPI, RSU, Safety, Female, Infertility, New Drug Application, Endometriosis, Pregnancy, Man, LinkedIn, GLOBE, Twitter, Food, RWS, Employment, NYSE, Woman, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, EC, Pharmaceutical industry

The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.

Key Points: 
  • The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
  • The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 231,800 common shares ofMyovant.
  • The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.

Profound Medical to Participate in the Cowen 7th Annual FutureHealth Conference

Retrieved on: 
Thursday, June 16, 2022
Uterine fibroid, FDA, Hyperthermia, Prostate cancer, TSX, Technology, CE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, National Medical Products Administration, Company, Health Canada, High-intensity focused ultrasound, NASDAQ, Device, Bone, MRI, Food, Urethra, Rectum, Conference, Eastern Time Zone, Humanitarian Device Exemption, International Medical Corps, GLOBE, Hematuria, Pharmaceutical industry, Medical imaging

While the panel discussion will be accessible to registered conference participants, due to the format of the event, no webcast will be available.

Key Points: 
  • While the panel discussion will be accessible to registered conference participants, due to the format of the event, no webcast will be available.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Retrieved on: 
Friday, June 3, 2022
Goldman Sachs, Woman, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infertility, Conference, Man, Roivant Sciences, Endometriosis, Food, Business, LinkedIn, EC, Investor, Female, Uterine fibroid, USPI, FDA, Goldman, GLOBE, Review, NYSE, Twitter, New Drug Application, RWS, Pregnancy, Safety, Pharmaceutical industry

BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time.

Key Points: 
  • BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time.
  • Investors and the general public are invited to listen to the Goldman Sachs fireside chat, which will be accessible on the Events page under the Investors & Media section of theMyovantwebsite at www.myovant.com .
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.
  • Founded in 2016,Myovanthas executed five successful Phase 3 clinical trials across oncology and womens health leading to two regulatory approvals by theU.S.

Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference

Retrieved on: 
Thursday, June 2, 2022
Company, Conference, Urethra, Food, Webcast, Hyperthermia, CE, Investor, International Medical Corps, Bone, Prostate cancer, Humanitarian Device Exemption, Uterine fibroid, FDA, GLOBE, Health Canada, Rectum, Technology, TSX, NASDAQ, Hematuria, National Medical Products Administration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRI, Pharmaceutical industry, Medical imaging

TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Companys business at the 2022 Jefferies Global Healthcare Conference in New York City on Thursday, June 9, 2022 at 4:30 p.m. Eastern Time.

Key Points: 
  • TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Companys business at the 2022 Jefferies Global Healthcare Conference in New York City on Thursday, June 9, 2022 at 4:30 p.m. Eastern Time.
  • The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.

ObsEva Announces Corporate Updates

Retrieved on: 
Friday, May 27, 2022
SIX Swiss Exchange, Report, U.S. Securities and Exchange Commission, Birth certificate, Risk, Private Securities Litigation Reform Act, Uterine fibroid, NASDAQ, Coronavirus, Nasdaq, Endometriosis, Investor, Failure, Form 6-K, Amendment, JGB, Pregnancy, Drug development, SEC, Security (finance), Pharmaceutical industry

The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022.

Key Points: 
  • The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022.
  • In exchange, ObsEva has agreed to further restrictions on the existing account control agreement in favor of JGB, which secures the Securities Purchase Agreement.
  • ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health and pregnancy.
  • Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor.

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

Retrieved on: 
Wednesday, May 25, 2022
International Society, Catholic higher education, HMB, Gynecological Endocrinology, EDELWEISS, Uterine fibroid, Catholic University of Leuven (1834–1968), Doctor of Philosophy, World Congress, PRIMROSE, NASDAQ, LGX, Constipation, Gonadotropin-releasing hormone, Treatment, DYS, Uterus, MBL, Congress, Yale School of Medicine, Safety, Dysmenorrhea, ABT, Pharmaceutical industry, Birth control, Medical imaging, Endometriosis, Woman, MD

GENEVA, Switzerland May 25, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.

Key Points: 
  • GENEVA, Switzerland May 25, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.
  • The encouraging data presented at these important medical congresses highlight the differentiated therapeutic potential of linzagolix to better address the individual needs of women with uterine fibroids and endometriosis, said Dr. Brandi Howard, Chief Clinical Officer of ObsEva.
  • These data demonstrate that linzagolix with or without add-back therapy (ABT) significantly reduced heavy menstrual bleeding due to uterine fibroids.
  • Linzagolix is an investigational novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile1,2,3.